3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Cyclophosphamide
59
Dexamethasone
56
Melphalan
48
Peripheral Blood Stem Cell Transplantation
37
Busulfan
34
Bortezomib
32
fludarabine phosphate
29
Lenalidomide
27
Filgrastim
27
Tacrolimus
24
Antilymphocyte Serum
24
Thalidomide
22
Mycophenolic Acid
22
Radiotherapy
21
Methotrexate
15
Cyclosporine
15
Etoposide
14
sargramostim
13
Granulocyte Colony-Stimulating Factor
11
Whole-Body Irradiation
10
Methylprednisolone
10
Interferon-alpha
10
fludarabine
9
daratumumab
9
Carmustine
9
carfilzomib
7
Rituximab
7
Prednisone
7
Cytarabine
7
Cord Blood Stem Cell Transplantation
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Plasma Cell
×
crexavibart
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn